OpenEvidence Valued at $12B After $250M Series D to Expand Medical AI
Event summary
- OpenEvidence closed a $250M Series D round, valuing the company at $12B.
- The round was co-led by Thrive Capital and DST Global, with participation from existing investors including Sequoia, Google Ventures, and Nvidia.
- OpenEvidence is an AI-powered medical search engine used by more American physicians than all other AI tools combined.
- The company supported 18M clinical consultations in December 2025, up from 3M monthly consultations a year prior.
- OpenEvidence became one of the fastest companies to reach $100M in annual revenue, less than a year after building out its commercial team.
The big picture
OpenEvidence's $250M Series D round underscores the growing importance of AI in healthcare, particularly in enhancing the efficiency and accuracy of medical research and practice. The company's rapid adoption by physicians highlights a shift towards AI-driven decision-making tools in clinical settings. With a valuation of $12B, OpenEvidence is positioning itself as a key player in the medical AI segment, leveraging exclusive partnerships with leading medical journals and associations to maintain its competitive edge.
What we're watching
- Market Dominance
- Whether OpenEvidence can sustain its vertical dominance in medical AI amid rapid adoption and competition.
- Regulatory Scrutiny
- The pace at which regulatory bodies may scrutinize AI-driven medical advice platforms.
- Technological Advancements
- How OpenEvidence's multi-AI agentic architecture will evolve and impact the accuracy of medical answers.
Related topics